Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
descartes-15
- Development stage
- Discontinued
- Lead developer
- Cartesian Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
Descartes-15 is a next-generation autologous B cell maturation antigen (BCMA)-directed mRNA-engineered chimeric antigen receptor T-cell therapy (CAR-T) developed by Cartesian Therapeutics. It is designed to have predictable and controllable pharmacokinetics with technological advances that enhance CAR stability even in the presence of target-driven suppression of CAR. Unlike conventional DNA-based CAR-T therapies, Descartes-15 does not require preconditioning chemotherapy and avoids the risk of genomic integration by using mRNA engineering rather than integrating vectors. Preclinical studies have shown that Descartes-15 achieves approximately ten-fold higher CAR expression and selective target-specific killing compared to earlier candidates such as Descartes-08. The drug is currently being evaluated in Phase 1 clinical trials for relapsed/refractory multiple myeloma and has preclinical development for autoimmune disorders and solid tumors[1][2][3][5][6].
- Other names
- anti-BCMA mRNA CAR-T cell therapyanti-BCMA mRNA chimeric antigen receptor T cell therapy
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on descartes-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on descartes-15.